(c) 2009 Society MI-503 chemical structure of Chemical Industry”
“Objective: To compare the performance of the ferric reducing capacity (FRC) assay with the ferric reducing antioxidant power (FRAP) assay to measure the total antioxidant capacity (TAC) of serum samples.
Methods: Serum from 10 healthy ethnic Chinese adult volunteers was assayed for TAC levels. A Sunrise absorbance reader was used for measurements of absorbance changes. The kinetic force of the reaction was monitored at 2-minute intervals for as long as 10 minutes at room temperature. The difference in absorbance between the blank and sample specimens was calculated.
Results: No
significant increase in signal was observed at the 2-minute mark for the vitamin C reaction kinetic manifestations of FRC or FRAP. However, over time an increase was observed in absorbance levels
in readings with serum. The dose-response lines for both assays showed strong linearity up to the 2000 mu mol/L concentration of vitamin C tested at the 4-minute mark. Serum TAC ranged from 264 to 610 mu mol/L of vitamin C equivalents for FRC and from 172 to 418 for FRAP. A strong positive correlation was observed between the TAC of the 10 serum samples measured by both assay methods.
Conclusions: The FRC assay is a useful alternative to the FRAP assay for measuring the TAC of serum due to its simplicity and speed of use and because it does not require specialized equipment. However, normal ranges should be established in the population intended before our results are put to clinical LXH254 molecular weight use.”
“We report a case of an 11-year-old girl with Coxiella burnetii
infection of a bovine jugular vein conduit which is an extremely rare manifestation of Q fever. The role of surgery in the management of C. burnetii endovascular infection and the use of serology are discussed.”
“Objective: To evaluate biomarkers of acute ischemic brain injury after surgical revascularization of the heart with the use of the heart-lung machine (ie, cardiopulmonary bypass Selleckchem Galardin [CPB]).
Methods: Twenty consecutive patients were divided into 2 groups: the first 10 patients received a potential neuroprotective human recombinant erythropoietin and the remaining 10 comprised the control group. Neurological complications were monitored by measuring serum concentrations of N-methyl-D-aspartate (NMDA)-receptor antibodies (NR2Ab), S100B protein, and neuron-specific enolase (NSE) before and during the first 5 days after surgery, comparing the neurological outcome with the results of MRI examinations.
Results: The results from the erythropoietin-treated group and the control group were similar, with a significant difference shown for the postoperative NSE.